Preventing Gastrointestinal Disturbance in Patients After Longitudinal Laparotomy. (ORE001PIIPOI)

A Multi-center, Randomized, Double Blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy of ORE-001 in Preventing Gastrointestinal Disturbance/ Intolerance in Patients After Longitudinal Laparotomy

This is a multi-center, randomized, double blind, placebo-controlled, phase 2 pilot efficacy study.

Study Overview

• Status: Recruiting
• Conditions: Ileus Postoperative
• Intervention / Treatment: Drug: Placebo; Drug: ORE001

Detailed Description

After assessing eligibility during a screening period (up to 4 weeks before planned surgery), up to 126 female patients are planned to be randomized to one of the two treatment groups.

After the surgery, at POD1 (Post Operative Day 1), all patients will receive the oral study drug (ORE-001 4x 100 mg or 4x placebo) 15-30 minutes before intake of the semi-solid main meal (lunch).

Clinical assessments of efficacy will be conducted based on I-FEED score and VAS (Visual Analogue Scale) abdominal pain score at POD1 to POD8 (or up to POD12 if extended), and the impact of the treatment on the Quality of Life (QoL) of the patients at POD8 (or at POD9 up to POD12 if extended) and at Follow up (FU) in comparison to Baseline values. The impact of the treatment on the QoL will be done by using the specific 36-Item Short Form Survey Instrument (SF-36) QoL questionnaire.

Adverse events (AEs) will be recorded from POD1 to EOS continuously, concomitant medication, and other assessments including vital signs and body weight will be recorded throughout the study (Screening to EOS (End Of Study)).

Urine pregnancy tests (only for females of childbearing potential) will be performed at Screening and Baseline. 12-lead ECG will be performed at Screening, Baseline, POD1 and at Day after last study drug administration.

Safety laboratory assessments on blood (hematology and biochemistry) and urine (routine dip stick test) will be conducted at Screening, Baseline, POD1 and from POD4 every second day until one day after last IMP administration to assess for any changes in the safety endpoints.

Blood albumin will be analyzed on Screening, Baseline, and every POD until one day after last IMP administration to assess for any changes in the safety endpoints.

Interleukin 6 will be analyzed at POD1 and POD6. Patients prematurely terminating the study after administration of at least one dose of the study drug should be subjected to a final examination including safety laboratory assessment.

• Study Type: Interventional
• Enrollment (Estimated): 126
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Ard Peeters, Prof.; Phone Number: 0652383983; Email: ardpeeters@orexa.nl

Study Locations

• Germany
  • Bonn, Germany
    • Recruiting
    • Universitätsklinikum Bonn (UKB).
    • Contact: A Mustea, Prof
  • Dusseldorf, Germany, 40489
    • Recruiting
    • Kaiserswerther Diakonie Florence-Nightingale- Krankenhaus
  • Wolfsburg, Germany, 38440
    • Recruiting
    • Klinikum Wolfsburg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patient must be able to understand the requirements of the study and give written informed consent prior to study start.
2. Female patients aged between 18 and 75 years (both inclusive).
3. Gynecologic surgery performed completely by longitudinal laparotomy.
4. Patient with ECOG Performance status up to 1.
5. Patient is highly likely to comply with the protocol and complete the study.
6. Patient agrees to be scheduled for peridural catheter (PDC).

Exclusion Criteria:

1. Patient has a history of gastrectomy, total colectomy, stoma creation, short bowel syndrome.
2. Patient has pre-operative ileus.
3. Patient is taking opioid analgesics longer than two post-operative days, exceeding a dosing of 35 mg morphine equivalent per day.
4. Chemotherapy treatment within 10 days after longitudinal surgery.
5. Smoking during the hospital stay.
6. Any contraindication as per summary of product characteristic for the usage of local anesthetics for PDC.
7. History of uncontrolled (at the discretion of the Investigator) cardiovascular, renal and/or hepatic failure.
8. History of severe allergic or anaphylactic reactions, especially to local anesthetics.
9. Clinically significant (at the discretion of the Investigator) deviation from the normal laboratory values.
10. Clinically significant (at the discretion of the Investigator) abnormal ECG.
11. Intake of any class 1B antiarrhythmic drugs if used for antiarrhythmic purpose (e.g., Lidocaine, Mexiletine, Phenytoin) and of any class 3 antiarrhythmic drugs - Kalium channel blockers (e.g., Amiodarone, Dronedarone, Sotalol, Ibutilide, Dofetilide, Bretylium).
12. Significant (at the discretion of the Investigator) symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection (especially with need of antibiotic treatment) within the past 2 weeks prior to study medication administration.
13. Experimental agent within 30 days or ten half-lives, whichever is longer, prior to study medication administration.
14. Pregnancy or planning to become pregnant during the study.
15. Any other condition, which in the opinion of the Investigator precludes the patient's participation in the study.
16. Patients with close affiliation with the Investigator or persons working at the respective study sites or patients who are an employee of the Sponsor.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Placebo treatment (4 tablets)	Drug: Placebo; Administration before major meal
Experimental: ORE001; ORE001 treatment (4 tablets)	Drug: ORE001; Administration before major meal; Other Names: Lidocaine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
I-FEED Post Operative Day 3	To evaluate the efficacy of oral ORE-001 compared to placebo in reducing the gastrointestinal disturbance/intolerance and the occurrence of postoperative ileus (POI) in patients after longitudinal laparotomy defined by scoring of the postoperative I-FEED scores at POD3. The I-FEED score ranges from 0 to 14. The higher the score the more severe are the symptoms.	Post Operative Day 3

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
I-FEED Post Operative Day 1	To evaluate the efficacy of oral ORE-001 compared to placebo in reducing the gastrointestinal disturbance/intolerance and the occurrence of postoperative ileus (POI) in patients after longitudinal laparotomy defined by scoring of the postoperative I-FEED scores at POD1. The I-FEED score ranges from 0 to 14. The higher the score the more severe are the symptoms.	Post Operative Day 1
I-FEED Post Operative Day 2	To evaluate the efficacy of oral ORE-001 compared to placebo in reducing the gastrointestinal disturbance/intolerance and the occurrence of postoperative ileus (POI) in patients after longitudinal laparotomy defined by scoring of the postoperative I-FEED scores at POD2. The I-FEED score ranges from 0 to 14. The higher the score the more severe are the symptoms.	Post Operative Day 2
I-FEED Post Operative Day 4	To evaluate the efficacy of oral ORE-001 compared to placebo in reducing the gastrointestinal disturbance/intolerance and the occurrence of postoperative ileus (POI) in patients after longitudinal laparotomy defined by scoring of the postoperative I-FEED scores at POD4. The I-FEED score ranges from 0 to 14. The higher the score the more severe are the symptoms.	Post Operative Day 4
I-FEED Post Operative Day 5	To evaluate the efficacy of oral ORE-001 compared to placebo in reducing the gastrointestinal disturbance/intolerance and the occurrence of postoperative ileus (POI) in patients after longitudinal laparotomy defined by scoring of the postoperative I-FEED scores at POD5. The I-FEED score ranges from 0 to 14. The higher the score the more severe are the symptoms.	Post Operative Day 5
I-FEED Post Operative Day 6	To evaluate the efficacy of oral ORE-001 compared to placebo in reducing the gastrointestinal disturbance/intolerance and the occurrence of postoperative ileus (POI) in patients after longitudinal laparotomy defined by scoring of the postoperative I-FEED scores at POD6. The I-FEED score ranges from 0 to 14. The higher the score the more severe are the symptoms.	Post Operative Day 6
I-FEED Post Operative Day 7	To evaluate the efficacy of oral ORE-001 compared to placebo in reducing the gastrointestinal disturbance/intolerance and the occurrence of postoperative ileus (POI) in patients after longitudinal laparotomy defined by scoring of the postoperative I-FEED scores at POD7. The I-FEED score ranges from 0 to 14. The higher the score the more severe are the symptoms.	Post Operative Day 7
I-FEED Post Operative Day 8	To evaluate the efficacy of oral ORE-001 compared to placebo in reducing the gastrointestinal disturbance/intolerance and the occurrence of postoperative ileus (POI) in patients after longitudinal laparotomy defined by scoring of the postoperative I-FEED scores at POD8. The I-FEED score ranges from 0 to 14. The higher the score the more severe are the symptoms.	Post Operative Day 8
I-FEED Post Operative Day 9	To evaluate the efficacy of oral ORE-001 compared to placebo in reducing the gastrointestinal disturbance/intolerance and the occurrence of postoperative ileus (POI) in patients after longitudinal laparotomy defined by scoring of the postoperative I-FEED scores at POD9. The I-FEED score ranges from 0 to 14. The higher the score the more severe are the symptoms.	Post Operative Day 9
I-FEED Post Operative Day 10	To evaluate the efficacy of oral ORE-001 compared to placebo in reducing the gastrointestinal disturbance/intolerance and the occurrence of postoperative ileus (POI) in patients after longitudinal laparotomy defined by scoring of the postoperative I-FEED scores at POD10. The I-FEED score ranges from 0 to 14. The higher the score the more severe are the symptoms.	Post Operative Day 10
I-FEED Post Operative Day 11	To evaluate the efficacy of oral ORE-001 compared to placebo in reducing the gastrointestinal disturbance/intolerance and the occurrence of postoperative ileus (POI) in patients after longitudinal laparotomy defined by scoring of the postoperative I-FEED scores at POD11. The I-FEED score ranges from 0 to 14. The higher the score the more severe are the symptoms.	Post Operative Day 11
I-FEED Post Operative Day 12	To evaluate the efficacy of oral ORE-001 compared to placebo in reducing the gastrointestinal disturbance/intolerance and the occurrence of postoperative ileus (POI) in patients after longitudinal laparotomy defined by scoring of the postoperative I-FEED scores at POD12. The I-FEED score ranges from 0 to 14. The higher the score the more severe are the symptoms.	Post Operative Day 12
Number of participants with treatment-related adverse events	To evaluate the safety and tolerability of oral ORE-001 in comparison to placebo in patients after longitudinal laparotomy at Baseline and up to POD9 (with possible extension to POD13).	Post Operative Day 1-13

Collaborators and Investigators

• Sponsor: Orexa BV
• Collaborators: QPS Holdings LLC

Study record dates

Study Major Dates

• Study Start (Actual): January 11, 2024
• Primary Completion (Estimated): December 31, 2025
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: June 9, 2023
• First Submitted That Met QC Criteria: June 19, 2023
• First Posted (Actual): June 28, 2023

Study Record Updates

• Last Update Posted (Actual): October 3, 2024
• Last Update Submitted That Met QC Criteria: October 1, 2024
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Keywords: local anesthetic
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Membrane Transport Modulators; Anesthetics, Local; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Lidocaine
• Other Study ID Numbers: CT-2022-503113-31

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No